Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CUE

Cue Biopharma Inc

Jun 09 • 04:00PM ET

30.44

+1.36 4.68 %

Healthcare • Biotechnology • USA • Micro • NASD

Peers: AGEN EDSA GNLX KZIA PYXS VRCA VTVT GALT IMUX SPRO

| Held by: VTI VXF DFAS AVSC DFAU DFMC AVTM

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.53	Insider Own	10.63%	Shs Outstand	4.20M	Perf Week	6.36%
Market Cap	127.86M	Forward P/E	-	EPS next Y	-9.45	Insider Trans	264.09%	Shs Float	3.75M	Perf Month	-13.03%
Enterprise Value	114.92M	PEG	-	EPS next Q	-1.69	Inst Own	16.98%	Short Float	6.80%	Perf Quarter	227.31%
Income	-19.52M	P/S	3.91	EPS this Y	20.95%	Inst Trans	-1.15%	Short Ratio	0.34	Perf Half Y	84.89%
Sales	32.73M	P/B	4.59	EPS next Y	-42.32%	ROA	-73.49%	Short Interest	0.26M	Perf YTD	232.24%
Book/sh	6.64	P/C	7.81	EPS next 5Y	-	ROE	-138.52%	52W High	41.42 -26.51%	Perf Year	59.29%
Cash/sh	3.90	P/FCF	-	EPS past 3/5Y	42.63% 29.04%	ROIC	-83.13%	52W Low	4.97 512.35%	Perf 3Y	-72.65%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	180.45% 54.16%	Gross Margin	99.01%	Volatility	15.99% 14.29%	Perf 5Y	-92.21%
Dividend TTM	-	EV/Sales	3.51	EPS Y/Y TTM	72.33%	Oper. Margin	-59.83%	ATR (14)	4.13	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.57	Sales Y/Y TTM	309.60%	Profit Margin	-59.65%	RSI (14)	62.40	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.57	EPS Q/Q	78.25%	SMA20	23.25%	Beta	2.43	Target Price	115.00
Payout	-	Debt/Eq	0.16	Sales Q/Q	1250.59%	SMA50	47.13%	Rel Volume	0.06	Prev Close	29.08
Employees	29	LT Debt/Eq	0.09	Earnings	May 14 AMC	SMA200	80.20%	Avg Volume	745.28K	Price	30.44
IPO	Jan 02, 2018	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	43,744	Change	4.68%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-13-24	Initiated	Jefferies	Buy	$6
Jun-26-23	Resumed	Oppenheimer	Outperform	$10
Nov-21-22	Initiated	Piper Sandler	Overweight	$7
Jan-13-22	Initiated	H.C. Wainwright	Buy	$20
Jan-03-22	Initiated	Craig Hallum	Buy	$28
Nov-24-20	Initiated	Berenberg	Buy	$30
Apr-09-20	Initiated	Stifel	Buy	$21
Jan-28-20	Initiated	BTIG Research	Buy	$26
Jan-22-20	Initiated	JMP Securities	Mkt Outperform	$22

Jun-02-26 04:05PM	Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution (GlobeNewswire) +18.93% -5.97%
May-21-26 04:05PM	Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference (GlobeNewswire) +6.82%
May-14-26 04:07PM	Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments (GlobeNewswire) -14.05% -9.16%
May-07-26 07:07PM	Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.15%
Apr-30-26 04:25PM	Cue Biopharma Announces $30 Million Private Placement (GlobeNewswire) +13.38% +106.38%
04:15PM	Loading…
04:15PM	Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody (GlobeNewswire)
04:05PM	Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company (GlobeNewswire)
Apr-22-26 08:37AM	Cue Biopharma Announces 1-for-30 Reverse Stock Split (GlobeNewswire) -13.42%
Apr-15-26 10:30AM	BC-Most Active Stocks (Associated Press) +65.37%
08:00AM	Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026 (GlobeNewswire)
Apr-10-26 10:30AM	BC-Most Active Stocks (Associated Press) +71.36%
Apr-08-26 08:00AM	Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement (GlobeNewswire) +45.48%
Apr-07-26 10:30AM	BC-Most Active Stocks (Associated Press) +6.33%
Mar-27-26 04:05PM	Cue Biopharma Announces CEO Transition (GlobeNewswire) -5.60%
Mar-26-26 08:00AM	Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026 (GlobeNewswire) -5.03%
04:05PM	Loading…
Mar-16-26 04:05PM	Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights (GlobeNewswire) +9.80% -12.84%
Mar-09-26 08:00AM	Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 (GlobeNewswire)
Feb-17-26 08:00AM	Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases (GlobeNewswire) -5.06%
Feb-12-26 08:00AM	Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer (GlobeNewswire) -6.75%
Dec-19-25 08:00AM	Cue Biopharma Announces Pricing of $10 Million Public Offering (GlobeNewswire) -21.58%
Dec-18-25 04:02PM	Cue Biopharma Announces Proposed Public Offering (GlobeNewswire) -14.50%
Nov-12-25 05:25PM	Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -7.19%
04:05PM	Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-07-25 05:55PM	CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-06-25 06:00PM	Puma Biotech (PBYI) Q3 Earnings and Revenues Top Estimates (Zacks)
08:00AM	Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors (GlobeNewswire)
Nov-05-25 06:35PM	Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Oct-30-25 08:20AM	Insmed (INSM) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Sep-29-25 09:00AM	Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates (GlobeNewswire)
Aug-21-25 08:00AM	Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference (GlobeNewswire)
08:00AM	Loading…
Aug-13-25 08:00AM	Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme (GlobeNewswire)
Aug-12-25 05:10PM	Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-08-25 07:45AM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-07-25 06:00PM	scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Jul-23-25 09:26AM	High-Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds (PR Newswire)
Jul-16-25 08:00AM	Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer (GlobeNewswire) +22.29%
Jul-01-25 04:05PM	Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies (GlobeNewswire)
Jun-24-25 04:48PM	Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease (GlobeNewswire) +10.43% +8.67%
May-12-25 05:10PM	Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
May-08-25 08:00AM	Cue Biopharma to Host Virtual Investor Event on May 15, 2025 (GlobeNewswire)
May-07-25 06:30PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-05-25 10:00AM	Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference (GlobeNewswire)
May-02-25 10:00AM	Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline (Zacks)
May-01-25 10:01AM	Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-30-25 09:30AM	Boehringer, Oxford University and Cumulus to explore brain activity in BPD (Pharmaceutical Technology)
Apr-16-25 04:58AM	Boehringer and Cue Biopharma to develop autoimmune therapies (Pharmaceutical Technology)
Apr-15-25 06:12PM	Cue Biopharma, Inc. (CUE) Business Update Call (Transcript) (Seeking Alpha)
02:00AM	Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases (GlobeNewswire)
Apr-14-25 10:23PM	Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering (GlobeNewswire)
05:05PM	Cue Biopharma Announces Proposed Public Offering (GlobeNewswire)
05:02PM	Cue Biopharma to Host Business Update Call and Webcast (GlobeNewswire)
05:00PM	Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases (GlobeNewswire)
Mar-31-25 05:15PM	Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -17.67%
04:20PM	Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (GlobeNewswire)
Mar-28-25 09:15AM	ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -8.00%
Nov-29-24 04:30PM	Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-25-24 08:00AM	Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-14-24 05:25PM	Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -17.00%
04:05PM	Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
08:00AM	Cue Biopharma Announces Strategic Organizational Transition (GlobeNewswire)
Nov-12-24 08:00AM	Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference (GlobeNewswire) -9.09%
Nov-08-24 01:30PM	Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting (GlobeNewswire)
Oct-04-24 09:00AM	Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting (GlobeNewswire) +41.60%
Sep-26-24 11:26PM	Cue Biopharma Announces Pricing of $12.0 Million Public Offering (GlobeNewswire) +49.61%
11:10PM	Cue Biopharma Announces Proposed Public Offering (GlobeNewswire)
Sep-09-24 08:00AM	Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer (GlobeNewswire)
Sep-03-24 08:00AM	Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference (GlobeNewswire) -8.96%
Aug-20-24 09:36AM	Q2 2024 Cue Biopharma Inc Earnings Call (Thomson Reuters StreetEvents) +13.68%
Aug-19-24 04:05PM	Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +11.93%
Aug-14-24 07:45PM	Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-13-24 08:00AM	Cue Biopharma to Host Business Update Call and Webcast (GlobeNewswire)
Jul-26-24 10:13AM	Cue Biopharma downsizes to focus on autoimmune pipeline (Pharmaceutical Technology)
Jul-25-24 04:05PM	Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements (GlobeNewswire)
Jun-04-24 08:00AM	Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting (GlobeNewswire) -5.45%
Jun-03-24 08:00AM	Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024 (GlobeNewswire)
May-30-24 03:30PM	Medical Moonshots: 3 Biotech Stocks Set to Skyrocket (InvestorPlace)
May-09-24 11:54PM	CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -9.14%
04:05PM	Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
May-08-24 08:00AM	Cue Biopharma to Present at the 20th Annual PEGS Boston Summit (GlobeNewswire) -12.39%
May-07-24 08:00AM	Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference (GlobeNewswire)
Apr-25-24 09:35AM	Here's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks (Zacks)
Apr-24-24 10:01AM	Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -5.33%
Apr-15-24 09:55AM	Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now (Zacks) -8.86%
Apr-09-24 07:36AM	Q4 2023 Cue Biopharma Inc Earnings Call (Thomson Reuters StreetEvents) -6.86%
03:02AM	Cue Biopharma Inc (CUE) Q4 2023 Earnings Call Transcript Highlights: Strategic Alliances and ... (GuruFocus.com)
Apr-08-24 04:05PM	Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights (GlobeNewswire) +10.27%
Apr-02-24 01:53PM	CUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
08:00AM	Cue Biopharma to Host Business Update Call and Webcast (GlobeNewswire)
Feb-29-24 10:00AM	Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium (GlobeNewswire)
Feb-06-24 08:00AM	Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) +5.46%
Dec-14-23 07:04AM	CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023 (InvestorPlace)
Nov-22-23 08:00AM	Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-12-23 12:55PM	Cue Biopharma, Inc. (NASDAQ:CUE) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:05PM	Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire) -11.32% +11.33%
Nov-07-23 08:00AM	Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November (GlobeNewswire)
Nov-03-23 12:00PM	Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023 (GlobeNewswire) +10.36%
Nov-02-23 08:00AM	Cue Biopharma to Host Business Update Call and Webcast (GlobeNewswire) +9.90%
Sep-28-23 05:39AM	Acadia (ACAD) Surges 8.3%: Is This an Indication of Further Gains? (Zacks)

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Principal Fin & Accounting Off. and Chief Financial & Business OfficerMs. Lucinda Warren

Ph.D.Dr. Shao-Lee Lin M.D.

Ph.D.Dr. Ronald D. Seidel III

Co-FounderDr. Rodolfo Jose Chaparro Ph.D.

Co-Founder and Chairman of Scientific & Clinical Advisory BoardDr. Steven C. Almo Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sarraf Pasha	Director	Dec 30 '25	Buy	0.31	323,857	99,747	323,857	Jan 02 04:00 PM
MATTEO GIACOMO LEVISETTI	Officer	Dec 29 '25	Proposed Sale	0.26	7,230	1,907		Dec 29 04:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CUE

Cue Biopharma Inc

Upgrade your Finviz experience